Commodity Channel Index
|Bid||5.50 x 800|
|Ask||6.95 x 800|
|Day's Range||6.27 - 6.68|
|52 Week Range||4.09 - 16.45|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 23, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Subscribe to Yahoo Finance Plus to view Fair Value for EXAI
OXFORD, England, March 16, 2023--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results.
OXFORD, England, March 15, 2023--Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. These abstracts highlight the components of Exscientia's approach to precision discovery, design and personalised medicine as well as planned innovation in the clinic.
OXFORD, England, March 14, 2023--Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds in development. IND-enabling studies are underway and the Company expects to provide an u